CN103989707A - Pig blood bacteriostat separated after pig blood limited enzymatic hydrolysis and extraction and preparation method thereof - Google Patents
Pig blood bacteriostat separated after pig blood limited enzymatic hydrolysis and extraction and preparation method thereof Download PDFInfo
- Publication number
- CN103989707A CN103989707A CN201410202784.6A CN201410202784A CN103989707A CN 103989707 A CN103989707 A CN 103989707A CN 201410202784 A CN201410202784 A CN 201410202784A CN 103989707 A CN103989707 A CN 103989707A
- Authority
- CN
- China
- Prior art keywords
- sus domestica
- antibacterial
- sanguis sus
- porphyrin
- pig blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention provides a pig blood bacteriostat separated after pig blood limited enzymatic hydrolysis and extraction and also provides a preparation process of the bacteriostat. The pig blood bacteriostat is a small peptide mixture with molecular weight of 500-3000, which is obtained by limited enzymatic hydrolysis, ultra-filtration and nano-filtration, has an F value of 14.5 and an isoelectric-point pI value of 4.4-9.7; in the mixture, acidic amino acid accounts for 25.6%, basic amino acid accounts for 10.3%, and the content of porphyrin and hydrolysate of the porphyrin is less than one thousandth; the mixture has very strong bacteriostatic activity. The extracted pig blood bacteriostat is a product obtained in a natural resource, has very good disinfectant and bacteriostatic capability, is different from a disinfectant and bacteriostatic product with common chemical components, does not generate a side effect on tissues and skin of a living body, and has the advantages of being safe and reliable, low in price, and relatively simple to prepare. Moreover, a novel choice is provided for preparing a disinfectant and bacteriostatic medicament and daily skin-cleaning articles for use.
Description
technical field:
the invention provides after a kind of Sanguis sus domestica limited enzymolysis extracts and separate the Sanguis sus domestica antibacterial obtaining, the preparation technology of this antibacterial is also provided simultaneously, belong to technological field of biochemistry.
background technology:
Nearly 600,000,000 of the annual pig carcass of China, accounts for world's pig slaughtering and measures 45%, and Sanguis sus domestica resource is very abundant, but at present except on a small quantity for making edible food, be not substantially developed, not only waste resource and contaminated environment.In fresh Sanguis sus domestica, contain abundant protein resource, the antibacterial extracting from Sanguis sus domestica has good biological bacteriostatic activity, can kill as multiple pathogen such as escherichia coli, staphylococcus aureus, Candida albicans.Meanwhile, adopting at present Production by Enzymes bioprotein preparation is current study hotspot, because its safety is high, inexpensive, be easy to promote the very big interest that causes people.The inhibiting-bacteria preparation stable in properties of extracting from Sanguis sus domestica, is rare stable biological inhibiting-bacteria preparation, can be widely used in field of biological pharmacy.
Traditional obtains antibacterial method by enzymatic isolation method from Sanguis sus domestica, first need to add anticoagulant in Sanguis sus domestica, as: heparin, sodium citrate, the increase to inherently safe attention degree along with scientific and technical development and people, the use of additives has become the event that more and more needs careful attention in natural prodcuts processing and production field at present.
In addition, from Sanguis sus domestica, obtain antibacterial by enzymatic isolation method, before enzymolysis, need to lure protein denaturation in blood into by acid adding, the way that adds alkali or heating, loose the unfolding of protein structure of degeneration can be by the fragments of peptides that proteolytic cleavage is slit into more, molecular weight is less.But this degeneration makes the structure of protein launch do not have repeatability, the quality stability that this has reduced enzymatic hydrolysate greatly, has improved the difficulty of quality control; Obtain in antibacterial technique at enzymatic isolation method, mainly to adopt the proteolytic enzymes that optimum temperature range is wider, restriction enzyme site is more such as papain, alkaline protease, pepsin, object is to obtain the as far as possible little peptide composition of molecular weight, shortcoming is the comparatively extensively poor reproducibility of restriction enzyme site of above-mentioned enzyme, and the technique that enzymolysis is prepared bioactive peptide is difficult to stable and concrete grasp.Meanwhile, adopt the controlled enzymatic hydrolysis time to finish enzyme digestion reaction, often other enzymolysis reaction, being often mingled in product from cleaved products of enzyme, thus affect the quality of enzymolysis product.And be ion-exchange chromatography, sieve chromatography and membrance separation in the main method that separates antibacterial from enzymolysis solution, only from sample treatment speed and amount, membrance separation > ion-exchange chromatography > sieve chromatography.Two kinds of technology of ion-exchange chromatography and sieve chromatography are respectively according to surface charge property and the molecular size range character of each peptide class component in enzymolysis solution, sample to be classified and initial gross separation, its advantage is that such technology is all very ripe in theoretical and practical application, shortcoming quantity of sample handling is little, pillar demutation is slow, is difficult to magnify produce and application; Membrane separation technique is to separate according to the molecular size of sample, and its advantage is fast, quantity of sample handling needs film greatly, hardly demutation and extra process are easy to magnify and produce and application.
Obtaining antibacterial technique for enzymatic isolation method, remove the process of porphyrin (haemachrome) and porphyrin hydrolysate from enzymolysis solution, is mainly activated carbon or macroporous resin adsorption, the organic solvent extractions such as chloroform; The use of activated carbon, macroporous resin is at absorption porphyrin and hydrolysate thereof the also bioactive peptide composition in adsorption of hydrolyzation liquid simultaneously, cause unnecessary loss, the use of the organic solvents such as chloroform, improves difficulty, cost and the quality control standard of technique, can reduce too the content of active component.
The described method that separates antibacterial from enzymolysis solution is mainly to adopt frozen drying method or high temperature spray-drying method to obtain the dry powder of antibacterial, make peptide class component under drying regime, ensure its biological activity, or existing with existing preparation, to ensure the biological activity of antibacterial.
summary of the invention:
The object of the present invention is to provide a kind of Sanguis sus domestica antibacterial, there is bacteriostatic activity.
The present invention also aims to provide a kind of preparation method of Sanguis sus domestica antibacterial, have high stability, repeatability, ease-to-operate, can sharp separation active component, remove porphyrin and hydrolysate thereof in product, the scale of being convenient to is amplified, and is applicable to the preparation method of suitability for industrialized production.
the Sanguis sus domestica antibacterial separating after Sanguis sus domestica limited enzymolysis disclosed by the invention extracts, is characterized in that:
It is the little peptide mixer that the molecular weight that obtains by ultrafiltration and nanofiltration means again after limited enzymolysis is 500 ~ 3000, F value is 14.5, isoelectric point, IP pI value is 4.4 ~ 9.7, in mixture, acidic amino acid accounts for 25.6%, basic amino acid accounts for 10.3%, the hydrolysate content of porphyrin and porphyrin is less than one thousandth, has very strong bacteriostatic activity;
Above-mentioned little peptide mixer is through nanoAcquity-UPLC BEH130 C
18chromatographic column separates, AB Sciex 5800 MALDI TOF/TOF mass spectral analyses, in this mixture aminoacid sequence as: SEQ NO.1, SEQ NO.2, SEQ NO.3 constituent content account for the more than 86% of Sanguis sus domestica antibacterial total protein content, and wherein the ratio of SEQ NO.1:SEQ NO.2:SEQ NO.3 is 1:1:1.
With escherichia coli (
escherichia coliaTCC 25922), staphylococcus aureus (
staphylocouus aureusaTCC 25923), pseudomonas aeruginosa (
pseudomonas aeruginosaaTCC 27853), Candida albicans (
monilia albicanaTCC 10231) be the active bacterium that detects, the bacteriostatic activity that detects SEQ NO.1, SEQ NO.2, tri-sequence components of SEQ NO.3 accounts for the more than 92% of the total bacteriostatic activity of Sanguis sus domestica antibacterial.
The preparation method of the Sanguis sus domestica antibacterial separating after Sanguis sus domestica limited enzymolysis of the present invention extracts, comprises the following steps:
1) fresh Sanguis sus domestica is fully mixed with 3～4 times of volume water gagings, under 100～150 rpms of conditions, stir 30～60 minutes, leave standstill 30 to 60 minutes, supernatant utilizes membrane separation technique through the ultrafiltration of hollow fiber filter membrane filter, the part below molecular cut off 30KDa;
2) filtrate below molecular weight 30KDa regulates pH to 8.0～8.5 with sodium hydroxide, and the ratio that is 1:1000～10000 according to mass volume ratio adds trypsin, enzymolysis 8～12 hours under 37 DEG C of conditions;
3) with acetic acid, enzymolysis solution is regulated to pH to 3.5～4.0, make enzyme deactivation enzymolysis reaction, heated and boiled 5 minutes, leaves standstill to room temperature, filters, and stays supernatant;
4) supernatant utilizes membrane separation technique through the ultrafiltration of hollow fiber filter membrane filter, the following part of molecular cut off 3KDa, and recycling membrane separation technique, by the above part of nanofiltration device molecular cut off 0.5KDa, both obtained;
5) the F value of Sanguis sus domestica antibacterial is 14.5, and aminoacid composition is shown in (table 1), and wherein acidic amino acid accounts for 25.6%, and basic amino acid accounts for 10.3%, and isoelectric point, IP pI distribution is 4.4 to 9.7, and porphyrin and porphyrin hydrolysate content are less than one thousandth.
The feature of preparation method of the present invention is: in blood, do not add anticoagulant, directly utilize the water of large volume to make erythrocyte carry out haemolysis, then utilize membrane separation technique to be less than the component of 30KDa through the direct isolated molecule amount of hollow cellulose filter membrane filter, remove not cell and the membrane structure of haemolysis; The way that do not adopt acid adding, adds alkali or heating is brought out the protein denaturation in blood; In the present invention, protease is to cut under the rock-steady structure of protein in blood, protein structure reproduction degree in the time of nearly rock-steady structure is high, the stability of protein structure, repeatability and the stability of enzymatic hydrolysate are improved, it is minimum that enzymatic hydrolysate difference between each batch reaches, and in different batches product, the content of three kinds of main antipathogenic composition SEQ NO.1, SEQ NO.2, SEQ NO.3 is between 89 ± 3%.
In the present invention, adopt the enzymolysis operation of pH protein in the condition of 8.0 to 8.5 is carried out blood, now in blood protein under nearly rock-steady structure state, general protein is in pH4～9 scope inner structure in reversible change state, and systematicness and reproducibility that its structure has height are called rock-steady structure; In the present invention, adopt trypsin, compare with papain, pepsin and alkaline protease that prior art adopts, trypsin has comparatively single-minded enzymolysis site, and the specificity in enzymolysis site has improved stability and the repeatability of enzymatic hydrolysate.
The present invention adopts acidifying with acetic acid and heating double technique to guarantee the termination of trypsin digestion reaction, inhibitory enzyme from the generation of cleaved products with sneak in product, improve stability and the repeatability of product.
More than bacteriostatic activity component in prior art in Sanguis sus domestica concentrates on molecular weight 3KDa, macromolecule antibacterial components activity in the time preserving and use is easy to lose because of folding, assembling and decomposing of molecule itself, so antibacterial activity component needs lyophilizing or existing with now preparation in background technology; There is not folding, gathering and the resolution problem of self in micromolecule amount bacteriostatic activity component of the present invention, liquid condition product is at room temperature preserved and had no above activity half a year and have loss.
Form
the aminoacid composition of Sanguis sus domestica antibacterial
| Aminoacid title | Aminoacid symbol | Amino acid content (mg/ml) |
| Aspartic acid (asparagines) | Asp | 5.333 |
| Glutamic acid (glutamic acid) | Glu | 2.341 |
| Serine (serine) | Ser | 1.140 |
| Histidine (histidine) | His | 1.934 |
| Arginine (arginine) | Arg | 0.7867 |
| Glycine (glycine) | Gly | 1.322 |
| Threonine (threonine) | Thr | 0.8148 |
| Proline (praline) | Pro | 0.7826 |
| Alanine (alanine) | Ala | 3.508 |
| Valine (valine) | Val | 2.596 |
| Methionine (methionine) (methionine) | Met | 0.3962 |
| Isoleucine (isoleucine) | Ile | 0.1139 |
| Leucine (leucine) | Leu | 3.533 |
| Tryptophan (tryptophan) | Trp | 0.5627 |
| Phenylalanine (phenylalanine) | Phe | 2.075 |
| Lysine (lysine) | Lys | 2.324 |
| Cysteine (cysteine) | Cys | 0.1038 |
Antibacterial aminoacid composition isoelectric point, IP (pI) wider distribution in the present invention, OD
220/ OD
280(F) value is higher, and porphyrin and porphyrin hydrolysate content are low, and product with stable quality; In porphyrin removal process, do not add the organic solvents such as active carbon, macroporous resin and chloroform, can avoid greatly the loss of active component, improve quality and the stability of product.
The bacteriostatic activity of above-mentioned Sanguis sus domestica antibacterial adopts cylinder plate method experimental test, result of the test shows: Sanguis sus domestica antibacterial of the present invention has to be killed significantly as encountered pathogenic bacterias such as escherichia coli, staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, can be used for preparing the article of everyday use of sterilization, antibacterial medicines and cleaning skin.
good effect of the present invention is:sanguis sus domestica antibacterial is the product obtaining in natural resources, has good bactericidal ability, is different from the bactericidal product of general chemical composition, can not have side effects to the tissue of organism, skin, have safe and reliable, cheap, the relatively simple advantage of preparation.For preparing bacteriostasis and sterilization medicine and daily skin cleaning article aspect provides new selection.
detailed description of the invention:
Embodiment is used for further illustrating the present invention below, but content of the present invention is not limited to this.
embodiment 1
One, the preparation of Sanguis sus domestica antibacterial:
1) getting 1 liter of fresh Sanguis sus domestica fully mixes 30 minutes with 3 liters of distilled water, under 100～150 rpms of conditions, stir 30～60 minutes, leave standstill 30 to 60 minutes, supernatant utilizes membrane separating method through the ultrafiltration of hollow cellulose filter membrane filter, the part below molecular cut off 30KDa;
2) by the solution obtaining in step 1), regulate pH to 8.0 with sodium hydroxide, adding mass volume ratio is the trypsin of 1:1000 enzymolysis 8 hours under 37 DEG C of conditions;
3) with acetic acid, enzymolysis solution is regulated to pH to 4.0, make enzyme deactivation enzymolysis reaction, heated and boiled 5 minutes, leaves standstill to room temperature, stays supernatant;
4) supernatant is through ultrafilter ultrafiltration, the following part of molecular cut off 3KDa, then by the above part of nanofiltration device molecular cut off 500, both must.
5), in step 4) products obtained therefrom, the content of three kinds of main effective bacteriostatic ingredients SEQ NO.1, SEQ NO.2, SEQ NO.3 is 91%, wherein SEQ NO.1:SEQ NO.2:SEQ NO.3 ratio be 1:! : 1; The F value of Sanguis sus domestica antibacterial is 14.5, and aminoacid composition is shown in (table 1), and wherein acidic amino acid accounts for 25.6%, and basic amino acid accounts for 10.3%, and isoelectric point, IP pI distribution is 4.4 to 9.7, and porphyrin and porphyrin hydrolysate content are less than one thousandth.
Inhibitory potency test
Two, bacteriostatic test
1) strain
Escherichia coli
escherichia coliaTCC 25922
Staphylococcus aureus
staphylocouus aureusaTCC 25923
Pseudomonas aeruginosa
pseudomonas aeruginosaaTCC 27853
Candida albicans
monilia albicanaTCC 10231
Clinical multi-drug resistant staphylococcus aureus (main drug resistance title piperacillin, ofloxacin, cefotaxime, sulfamethoxazole.Third generation cephalosporin, piperazine ketone)
Clinical multi-drug resistant Pseudomonas aeruginosa (main drug resistance title penicillin, erythromycin, ofloxacin, methicillin)
2) method
Above-mentioned each strain is carried out to strain recovery, is cultured to exponential phase, with strain the corresponding fluid medium of kind be separately diluted to 10
5～10
6cFU/ml, adopts spreader that the bacterium liquid of dilution is evenly coated on corresponding kind solid medium.Oxford cup is placed on solid medium, and every part of Sanguis sus domestica antibacterial sample is established 3 contrasts, and establishes negative control, solid medium is placed in to 37 DEG C and cultivates 16～24 hours.Rear employing vernier caliper measurement antibacterial circle diameter.Test repeats 3～5 times.
(3) result
| Strain name | The every 100 μ g Sanguis sus domestica antibacterial of antibacterial circle diameter/mm() | Negative control diameter/mm(100 μ g) |
| ATCC 25922 | 14.3～15.2 | - |
| ATCC 25923 | 15.5～16.3 | - |
| ATCC 27853 | 14.8～15.4 | - |
| ATCC 10231 | 8.9～10.5 | - |
| Clinical multi-drug resistant staphylococcus aureus | 14.8～15.9 | - |
| Clinical multi-drug resistant Pseudomonas aeruginosa | 13.9～15.5 | - |
Note: 1) inhibition zone standard-be less than 8mm without bacteriostasis;-be greater than 8mm and have bacteriostasis;
2) inhibition zone=actual measurement inhibition zone-Oxford cup external diameter (7.8mm)
conclusion:above-mentioned test shows, Sanguis sus domestica antibacterial of the present invention has obvious effect killing and suppress aspect the conventional bacterium such as escherichia coli, staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans and some clinical multi-drug resistant antibacterials, can be used for preparing bactericidal medicine and daily skin cleaning article.
embodiment 2
One, the preparation of Sanguis sus domestica antibacterial:
1) getting 1 liter of fresh Sanguis sus domestica fully mixes 30 minutes with 3 liters of distilled water, under 100～150 rpms of conditions, stir 30～60 minutes, leave standstill 30 to 60 minutes, supernatant utilizes membrane separation technique through the ultrafiltration of hollow cellulose filter membrane filter, the part below ultrafiltration molecular cut off 30KDa;
2) sodium hydrate buffer solution for obtained component in step 1) is regulated to pH to 8.5, adding mass volume ratio is the trypsin of 1:5000 enzymolysis 12 hours under 37 DEG C of conditions;
3) with acetic acid, enzymolysis solution is regulated to pH to 3.5, make enzyme deactivation enzymolysis reaction, heated and boiled 5 minutes, leaves standstill to room temperature, stays supernatant;
4) supernatant is through ultrafilter ultrafiltration, the following part of molecular cut off 3KDa, then by the above part of nanofiltration device molecular cut off 0.5KDa, both must.
5) in step 4) products obtained therefrom, the content of three kinds of main effective bacteriostatic ingredients SEQ NO.1, SEQ NO.2, SEQ NO.3 is 86%, and wherein SEQ NO.1:SEQ NO.2:SEQ NO.3 ratio is 1:1:1.The F value of Sanguis sus domestica antibacterial is 14.5, and aminoacid composition is shown in (table 1), and wherein acidic amino acid accounts for 25.6%, and basic amino acid accounts for 10.3%, and isoelectric point, IP pI distribution is 4.4 to 9.7, and porphyrin and porphyrin hydrolysate content are less than one thousandth.
Two, inhibitory potency test:
1) strain
Escherichia coli
escherichia coliaTCC 25922
Staphylococcus aureus
staphylocouus aureusaTCC 25923
Pseudomonas aeruginosa
pseudomonas aeruginosaaTCC 27853
Candida albicans
monilia albicanaTCC 10231
Clinical multi-drug resistant staphylococcus aureus (main drug resistance title piperacillin, ofloxacin, cefotaxime, sulfamethoxazole.Third generation cephalosporin, piperazine ketone)
Clinical multi-drug resistant Pseudomonas aeruginosa (main drug resistance title penicillin, erythromycin, ofloxacin, methicillin)
2) method:
Above-mentioned each strain is carried out to strain recovery, is cultured to exponential phase, with strain the corresponding fluid medium of kind be separately diluted to 10
5～10
6cFU/ml, adopts spreader that the bacterium liquid of dilution is evenly coated on corresponding kind solid medium.Oxford cup is placed on solid medium, and every part of Sanguis sus domestica antibacterial sample is established 3 contrasts, and establishes negative control, solid medium is placed in to 37 DEG C and cultivates 16～24 hours.Rear employing vernier caliper measurement antibacterial circle diameter.Test repeats 3～5 times.
3) result:
| Strain name | The every 100 μ g Sanguis sus domestica antibacterial of antibacterial circle diameter/mm() | Negative control diameter/mm(100 μ g) |
| ATCC 25922 | 14.6～15.8 | - |
| ATCC 25923 | 15.4～16.7 | - |
| ATCC 27853 | 14.0～15.5 | - |
| ATCC 10231 | 9.2～11.0 | - |
| Clinical multi-drug resistant staphylococcus aureus | 14.3～15.7 | - |
| Clinical multi-drug resistant Pseudomonas aeruginosa | 14.1～16.0 | - |
Note: 1) inhibition zone standard-be less than 8mm without bacteriostasis;-be greater than 8mm and have bacteriostasis;
2) inhibition zone=actual measurement inhibition zone-Oxford cup external diameter (7.8mm)
conclusion:above-mentioned test shows, Sanguis sus domestica antibacterial of the present invention has obvious effect killing and suppress aspect the conventional bacterium such as escherichia coli, staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans and some clinical multi-drug resistant antibacterials, can be used for preparing bactericidal medicine and daily skin cleaning article.
<110> Jilin University
Sanguis sus domestica antibacterial separating after <120> Sanguis sus domestica limited enzymolysis extracts and preparation method thereof
<160> 3
<210> 1
<211> 16
<212> PRT
<213> PIG
<400> 1
Val Leu Ser Ala Ala Asp Lys Ala Asn Val Lys Ala Ala Trp Gly Lys
1 5 10 15
<210> 2
<211> 12
<212> PRT
<213> PIG
<400> 1
Val Val Ala Gly Val Ala Asn Ala Leu Ala His Lys
1 5 10
<210> 3
<211> 15
<212> PRT
<213> PIG
<400> 1
Ala His Gly Lys Lys Val Leu Gln Ser Phe Ser Asp Gly Leu Lys
1 5 10 15
Claims (2)
1. the Sanguis sus domestica antibacterial that Sanguis sus domestica limited enzymolysis separates after extracting, is characterized in that;
Molecular weight is 500 ~ 3000 little peptide mixer, and F value is 14.5, and isoelectric point, IP pI value is 4.4 ~ 9.7, and in mixture, acidic amino acid accounts for 25.6%, and basic amino acid accounts for 10.3%, and the hydrolysate content of porphyrin and porphyrin is less than one thousandth, has very strong bacteriostatic activity;
The aminoacid sequence of antibacterial main component as: as shown in SEQ NO.1, SEQ NO.2, SEQ NO.3, ratio is 1:1:1.
2. the preparation method of the Sanguis sus domestica antibacterial separating after extracting according to Sanguis sus domestica limited enzymolysis described in claims 1, comprises the following steps:
1) fresh Sanguis sus domestica is fully mixed with 3～4 times of volume water gagings, under 100～150 rpms of conditions, stir 30～60 minutes, leave standstill 30 to 60 minutes, supernatant utilizes membrane separation technique through the ultrafiltration of hollow fiber filter membrane filter, the part below molecular cut off 30KDa;
2) in step 1), obtained component regulates pH to 8.0～8.5 with sodium hydroxide, and the ratio that is 1:1000～10000 according to mass volume ratio adds trypsin, enzymolysis 8～12 hours under 37 DEG C of conditions;
3) with acetic acid, enzymolysis solution is regulated to pH to 3.5～4.0, make enzyme deactivation enzymolysis reaction, heated and boiled 5 minutes, leaves standstill to room temperature, filters, and stays supernatant;
4) supernatant is through the ultrafiltration of hollow fiber filter membrane filter, the following part of molecular cut off 3KDa, then by the above part of nanofiltration device molecular cut off 0.5KDa, both must;
5) the F value of Sanguis sus domestica antibacterial is 14.5, and aminoacid composition is shown in (table 1), and wherein acidic amino acid accounts for 25.6%, and it is 4.4 to 9.7 that basic amino acid accounts for 10.3%, pI distribution, and porphyrin and porphyrin hydrolysate content are less than one thousandth.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410202784.6A CN103989707B (en) | 2014-05-14 | 2014-05-14 | Detached Sanguis sus domestica antibacterial and preparation method thereof after a kind of Sanguis sus domestica limited enzymolysis extraction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410202784.6A CN103989707B (en) | 2014-05-14 | 2014-05-14 | Detached Sanguis sus domestica antibacterial and preparation method thereof after a kind of Sanguis sus domestica limited enzymolysis extraction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103989707A true CN103989707A (en) | 2014-08-20 |
| CN103989707B CN103989707B (en) | 2017-03-15 |
Family
ID=51304210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410202784.6A Expired - Fee Related CN103989707B (en) | 2014-05-14 | 2014-05-14 | Detached Sanguis sus domestica antibacterial and preparation method thereof after a kind of Sanguis sus domestica limited enzymolysis extraction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103989707B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105859874A (en) * | 2016-05-26 | 2016-08-17 | 陈石良 | Preparation method for producing pig haemocyte active small peptide powder through one-step method |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108165598A (en) * | 2018-02-08 | 2018-06-15 | 金华市铁骑士生物科技有限公司 | A kind of extracting method of pig blood antibiotic peptide |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991012270A2 (en) * | 1990-02-14 | 1991-08-22 | Genentech, Inc. | Novel platelet aggregation inhibitors from the leech |
| CN1832773A (en) * | 2003-06-05 | 2006-09-13 | 巴克斯特国际有限公司 | Methods for repairing and regenerating human dura mater |
-
2014
- 2014-05-14 CN CN201410202784.6A patent/CN103989707B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991012270A2 (en) * | 1990-02-14 | 1991-08-22 | Genentech, Inc. | Novel platelet aggregation inhibitors from the leech |
| CN1832773A (en) * | 2003-06-05 | 2006-09-13 | 巴克斯特国际有限公司 | Methods for repairing and regenerating human dura mater |
Non-Patent Citations (3)
| Title |
|---|
| 余奕珂，等。: "以猪血为蛋白源的生物活性肽的研究进展", 《精细与专用化学品》 * |
| 刘琪，等。: "猪血抗菌活性物质制备及其抗菌活性研究", 《第三届泛环渤海生物化学与分子生物学会-2012年学术交流会论文集》 * |
| 庞美霞，等。: "酶法分离纯化猪血血红素的工艺及应用研究进展", 《武汉工业学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105859874A (en) * | 2016-05-26 | 2016-08-17 | 陈石良 | Preparation method for producing pig haemocyte active small peptide powder through one-step method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103989707B (en) | 2017-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gao et al. | Identification and antimicrobial activity evaluation of three peptides from laba garlic and the related mechanism | |
| CN105586379B (en) | A kind of preparation method with the collagen active peptide for inhibiting cancer cell multiplication effect | |
| US8450100B2 (en) | Collagen peptide having immune-enhancing activity from Cyanea nozakii and preparation method and uses thereof | |
| CN104710511B (en) | Iron chelating peptide derived from hairtail fish protein and preparation method and application thereof | |
| Kim et al. | Purification of a novel anticancer peptide from enzymatic hydrolysate of Mytilus coruscus | |
| CN101020715B (en) | Process of extracting and preparing deer nerve growth factor (DEER NGF) | |
| CN108601783A (en) | Compatible solute or solute mixture for preventing or treating barrier defect disease in epithelial tissue | |
| Zhang et al. | Antimicrobial Capacity and Antioxidant Activity of Enzymatic Hydrolysates of Protein from R ushan Bay Oyster (C rassostrea gigas) | |
| CN109371088A (en) | A kind of preparation method of sea cucumber active peptide | |
| CN106963718A (en) | A kind of cosmetic composition with anti aging effect effect | |
| WO2015108333A1 (en) | Analogue peptide cma3 derived from cm-ma peptide and use thereof | |
| CN103989707A (en) | Pig blood bacteriostat separated after pig blood limited enzymatic hydrolysis and extraction and preparation method thereof | |
| CN110590908B (en) | Micropterus-derived antibacterial peptide additive and preparation method thereof | |
| CN106366169B (en) | Anti-tumor protein extract and preparation method and application in a kind of Ramaria botrytis | |
| US11077170B2 (en) | Antimicrobial peptide from skate skin and uses thereof | |
| JP2016056116A (en) | Composition for promoting collagen production | |
| JP6464507B2 (en) | Antiviral and antibacterial agents | |
| US3394120A (en) | Process of extracting protein from mistletoe and resultant product | |
| KR20120079977A (en) | Anticancer composition comprising enzymatic hydrolysates of ruditapes philippinarum | |
| CN109400669B (en) | Extraction method and application of micromolecular protein of walnut kernel peel | |
| KR20120049047A (en) | Antiinflammatory composition comprising enzymatic hydrolysates of crassostrea gigas | |
| KR101716765B1 (en) | Novel antifungal peptide BA-1 isolated from Bacillus amyloliquefaciens EML-CAP-03 and use thereof | |
| KR102397841B1 (en) | Method for producing deer antler extract with enhanced S-GAG and sialic acid content | |
| JP2526362B2 (en) | Cosmetics | |
| US20190091287A1 (en) | Plant fractions having anti-pathogenesis properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170315 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |